Company news
Chimin Health Management Co., Ltd. Class A (SSE:603222) news
Chimin Health Management Co., Ltd. Class A news releases on 6ix. Latest, Sep 24, 2026: "Chimin Health Management Co., Ltd."Announcement on Results…
Press releases & updates
"Chimin Health Management Co., Ltd."Announcement on Results of Shareholding Reduction by Shareholder
September 23, 2026
"Chimin Health Management Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
September 22, 2026
"Chimin Health Management Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholders Reaching an Integral Multiple of 1%
September 18, 2026
"Chimin Health Management Co., Ltd."Announcement on Release of Pledge of Certain Shares Held by Shareholder
September 15, 2026
"Chimin Health Management Co., Ltd."Announcement on Resolutions of the 7th Meeting of the 6th Board of Directors
August 25, 2026
"Chimin Health Management Co., Ltd."Announcement on Shareholding Reduction Plan of Shareholders
August 20, 2026
"Chimin Health Management Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
August 5, 2026
"Chimin Health Management Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
August 4, 2026
"Chimin Health Management Co., Ltd."Announcement on Process of Asset Acquisition
July 31, 2026
"Chimin Health Management Co., Ltd."Announcement on Termination of the Share Transfer under Agreement by the Controlling Shareholder
July 22, 2026
"Chimin Health Management Co., Ltd."Indicative Announcement on the Share Transfer by Agreement and Changes in Equity Interests of Shareholders
July 20, 2026
"Chimin Health Management Co., Ltd."Announcement on the Semi-annual Performance for 2026
July 14, 2026
Announcement on Outline of the Performance Briefing for 2025 and Q1 2026
May 27, 2026
Announcement on Notice of Approval for the Transfer of Patent Rights Obtained by Holding Subsidiaries
May 25, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 18, 2026
Announcement on Termination of the Controlling Shareholder's Agreement to Transfer Shares
May 8, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
April 29, 2026
Announcement on Termination of Capital Increase for Share Expansion by Wholly-owned Subsidiary
April 27, 2026
Indicative Announcement on Changing the Disclosure Date of the 2025 Annual Report
April 23, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial by the Holding Subsidiary’s Pharmaceuticals
April 8, 2026
Announcement on Abnormal Fluctuations in Stock Trading
April 7, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
April 2, 2026
Announcement on Expiration of Share Repurchase Period and Results of Share Repurchase
March 19, 2026
Announcement on Capital Increase of Subsidiary to Introduce Strategic Investors and Related Party Transactions
March 17, 2026
Indicative Announcement on Negotiated Transfer of Shares by Shareholder and Change in Shareholders' Rights and Interests
March 6, 2026
Announcement on the Repurchased Company Shares Reaching 2% and Repurchase Progress
February 27, 2026
Announcement on the Repurchased Company Shares Reaching 1% and Repurchase Progress
January 30, 2026
Announcement on Expected Loss in Performance for 2025
January 23, 2026
Announcement on Providing Guarantee for Holding Subsidiary
January 5, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
December 31, 2025
Announcement on Completion of Establishment of a Joint Venture
December 23, 2025
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
December 15, 2025
Announcement on the Initiation of the Establishment of a Joint Venture
December 12, 2025
Announcement on Resolutions of the 1st Meeting of the 6th Board of Directors
December 2, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
December 1, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 24, 2025
Announcement on Early Termination of Shareholding Reduction Plan and Results of Shareholding Reduction by Shareholders
November 17, 2025
Announcement on Resolutions of the 23rd Meeting of the 5th Board of Directors
November 13, 2025
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
October 31, 2025
Report for Q3 2025
October 30, 2025
Announcement on Holding Subsidiary Obtaining Notice of Acceptance for Application of Drug Clinical Trials
September 29, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 16, 2025
Announcement on Risk Warning in Stock Trading
September 11, 2025
Announcement on Shareholding Reduction Plan for Shareholders
September 4, 2025
Announcement on Pledge of Partial Shares of Controlling Shareholder
August 25, 2025
2025 Semi-annual Report
August 20, 2025
Announcement on Abnormal Fluctuations in Stock Trading and Risk Warning
August 19, 2025
Announcement on Expected Decrease in Semi-annual Performance for 2025
July 11, 2025
Announcement on SSE’s Reply to Letter of Inquiry on Post Audit of 2024 Annual Report
July 3, 2025